🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› London
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in London

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2850 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 23 Sep 2026, 03:15 UTC
2850
Studies in scope
industry-sponsored, all four open statuses
1383
Recruiting now
open to new participants
542
Lead sponsors
across recruiting studies
Top sites
London 80 Manchester 25 Oxford 16 Glasgow 16 Nottingham 15
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca136 Merck Sharp & Dohme LLC98 Hoffmann-La Roche80 Janssen Research & Development, LLC73 Novartis Pharmaceuticals72 Clear sponsor filter
Site city
London80 Manchester25 Oxford16 Glasgow16 Nottingham15
All 86 cities
Target enrolment
to
80 of 2850 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Recruiting
An Early-Stage Study in Multiple Clinics of How Afimkibart May Affect the Body's Processing of Medicines That Rely on Cytochrome P450 Enzymes in Participants With Ulcerative Colitis
NCT07665723Active Ulcerative Colitis
Hoffmann-La Roche
Phase 1
25
Liverpool, London, Newcastle upon Tyne
2026-06-29
Recruiting
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
NCT07413939HER2-positive Breast Cancer
Hoffmann-La Roche
Phase 2/3
650
Leicester, London, Manchester, Montacute
2026-05-21
Recruiting
A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A
NCT07416526Hemophilia A
Hoffmann-La Roche
Phase 3
126
London, Cardiff
2026-05-15
Recruiting
A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)
NCT05199688Neuromyelitis Optica Spectrum Disorder, NMOSD
Hoffmann-La Roche
Phase 3
8
London
2026-05-06
Recruiting
A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A
NCT07416604Hemophilia A
Hoffmann-La Roche
Phase 3
360
London, Cardiff
2026-04-27
Recruiting
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
NCT07405801Breast Cancer
Hoffmann-La Roche
Phase 2
80
Leicester, London, Manchester
2026-04-07
Recruiting
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
NCT07351045Obesity or Overweight
Hoffmann-La Roche
Phase 3
2,000
Soham, Chippenham, Airdrie, Birmingham, Glasgow, Leicester, London, Newcastle upon Tyne
2026-03-16
Recruiting
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)
NCT07282574Progressive Multiple Sclerosis
Hoffmann-La Roche
Phase 2
360
Truro, London, Glasgow, Cardiff, Salford, Swansea
2026-03-10
Active, closed
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD)
NCT07234942Alzheimer's Disease
Hoffmann-La Roche
Phase 1
6
London, Southampton, Glasgow
2026-01-27
Recruiting
A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD
NCT06847542Neovascular Age-related Macular Degeneration
Hoffmann-La Roche
Phase 3
250
Leicester, Gloucester, London
2025-11-27
Recruiting
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
NCT07174310Parkinson's Disease
Hoffmann-La Roche
Phase 3
900
Dundee, Exeter, London, Newcastle, Oxford, Plymouth,Devon
2025-11-24
Recruiting
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
NCT07170150Alzheimers Disease
Hoffmann-La Roche
Phase 3
800
Bath, Birmingham, Edinburgh, Glasgow, London, Manchester, Oxford, Preston
2025-11-12
Recruiting
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
NCT06793215Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
Hoffmann-La Roche
Phase 3
600
Blackpool, Bristol, Canterbury, Cardiff, Hull, London, Maidstone, Oxford
2025-10-24
Recruiting
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
NCT07169578Alzheimers Disease
Hoffmann-La Roche
Phase 3
800
Bradford, Bristol, Chertsey, London, Newcastle, York
2025-09-17
Recruiting
A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease
NCT06998524Von Willebrand Disease, Type 3
Hoffmann-La Roche
Phase 3
75
London, Manchester
2025-06-27
Recruiting
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819891Moderately to Severely Active Crohns Disease
Hoffmann-La Roche
Phase 3
425
Bristol, Bury, Llanrhystud, London, Stockport
2025-05-12
Active, closed
An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care Treatment
NCT06883240Von Willebrand Disease, Type 3
Hoffmann-La Roche
Observational
44
London, Manchester
2025-04-29
Recruiting
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
NCT06790693Breast Cancer
Hoffmann-La Roche
Phase 3
450
Blackpool, Colchester, Essex, Edinburgh, Harlow, London, Northwood, Oxford, Sheffield
2025-04-09
Recruiting
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819878Moderately to Severely Active Crohns Disease
Hoffmann-La Roche
Phase 3
600
Cambridge, Harrow, Liverpool, London, Newcastle upon Tyne, North Shields, Nottingham
2025-03-17
Active, closed
A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration
NCT06795048Neovascular Age-related Macular Degeneration (nAMD)
Hoffmann-La Roche
Phase 4
274
Cardiff, Leeds, Liverpool, London, Newcastle upon Tyne, Wolverhampton
2025-03-14
Recruiting
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06588855Moderately to Severely Active Ulcerative Colitis
Hoffmann-La Roche
Phase 3
350
Leicester, Llanrhystud, London, Peterborough, Stockport, Wolverhampton
2024-12-11
Active, closed
A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)
NCT06534983Muscle-invasive Urothelial Carcinoma
Hoffmann-La Roche
Phase 2
62
Exeter, London
2024-12-09
Active, closed
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06497556Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
Hoffmann-La Roche
Phase 3
338
Cambridge, Cottingham, Glasgow, Leeds, London, Nottingham, Sutton, Torquay
2024-09-23
Active, closed
A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06589986Moderately to Severely Active Ulcerative Colitis
Hoffmann-La Roche
Phase 3
400
Cambridge, Liverpool, London
2024-09-17
Recruiting
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene Therapy
NCT05861999Muscular Atrophy, Spinal
Hoffmann-La Roche
Phase 4
28
London
2024-08-14
Recruiting
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene Therapy
NCT05861986Muscular Atrophy, Spinal
Hoffmann-La Roche
Phase 4
28
London
2024-05-30
Active, closed
A Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease (AD)
NCT06402838Alzheimer's Disease
Hoffmann-La Roche
Phase 2
256
Chertsey, Edinburgh, London, Manchester, Southampton
2024-05-02
Recruiting
A Study to Investigate Mechanisms of Resistance to Breast Cancer Therapies
NCT06274515Breast Cancer
Hoffmann-La Roche
Phase 4
320
Basingstoke, London, Manchester
2024-04-02
Active, closed
A First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants With Systemic Lupus Erythematosus
NCT05835986Systemic Lupus Erythematosus
Hoffmann-La Roche
Phase 1
70
London
2023-12-18
Active, closed
A Gene Delivery Study to Evaluate the Safety and Expression of Delandistrogene Moxeparvovec in Participants Under the Age of Four With Duchenne Muscular Dystrophy (DMD)
NCT06128564Duchenne Muscular Dystrophy
Hoffmann-La Roche
Phase 2
13
London, Oxford
2023-11-29
Recruiting
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
NCT06084936Lymphoma
Hoffmann-La Roche
Phase 3
182
Glasgow, Lincoln, London, Manchester, Oxford, Plymouth
2023-10-22
Active, closed
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
NCT06047080Large B-Cell Lymphoma
Hoffmann-La Roche
Phase 3
1,130
Barnet, Blackpool, Canterbury, Exeter, Glasgow, Leeds, London, Newcastle
2023-09-18
Active, closed
A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)
NCT05904886Hepatocellular Carcinoma
Hoffmann-La Roche
Phase 3
687
Edinburgh, London
2023-09-14
Active, closed
A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
NCT05797610Primary IgA Nephropathy
Hoffmann-La Roche
Phase 3
459
Cambridge, Leicester, London, Oxford, Salford
2023-08-08
Active, closed
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
NCT05878769Chronic Obstructive Pulmonary Disease
Hoffmann-La Roche
Phase 3
2,000
Cambridge, London, Bellshill, Bradford, Cardiff, Chesterfield, Chorley, Cottingham
2023-06-28
Recruiting
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
NCT05789082Non-Small Cell Lung Cancer
Hoffmann-La Roche
Phase 1/2
320
Glasgow, London
2023-06-20
Recruiting
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
NCT05646862Breast Cancer
Hoffmann-La Roche
Phase 3
420
Basingstoke, Blackpool, Dumfries, Edinburgh, Harlow, Livingston, London, Maidstone
2023-06-07
Active, closed
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
NCT05805501Renal Cell Carcinoma
Hoffmann-La Roche
Phase 2
199
London, Manchester
2023-04-21
Active, closed
A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer
NCT05645692Urothelial Cancer
Hoffmann-La Roche
Phase 2
204
London, Preston, Sutton
2023-04-13
Active, closed
A Study to Evaluate RO7204239 in Participants With Facioscapulohumeral Muscular Dystrophy
NCT05548556Facioscapulohumeral Muscular Dystrophy (FSHD)
Hoffmann-La Roche
Phase 2
51
London, Newcastle upon Tyne
2023-02-07
Active, closed
GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease
NCT05686551Huntington Disease
Hoffmann-La Roche
Phase 2
301
Birmingham, Cambridge, Leeds, London, Oxford, Southampton
2023-02-03
Active, closed
A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
NCT05476926Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, Branch Retinal Vein Occlusion
Hoffmann-La Roche
Observational
6,000
Bristol, Bedford, Torquay, Hull, Colchester, Gloucester, London, Maidstone
2022-11-21
Active, closed
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
NCT05169515Non-Hodgkin Lymphoma
Hoffmann-La Roche
Phase 1
121
Glasgow, London, Nottingham, Oxford
2022-10-26
Active, closed
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
NCT05296798Locally Advanced or Metastatic Breast Cancer
Hoffmann-La Roche
Phase 3
922
Bangor, Bath, Blackpool, Cleveland, London, Maidstone, Nottingham, Preston
2022-07-18
Active, closed
A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis
NCT05181618Severe Hemophilia A, Moderate Hemophilia A
Hoffmann-La Roche
Phase 4
136
London, Manchester
2022-06-20
Recruiting
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
NCT05039619Lupus Nephritis
Hoffmann-La Roche
Phase 2
40
Glasgow, Liverpool, London
2022-05-12
Active, closed
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis
NCT05269004Multiple Sclerosis
Hoffmann-La Roche
Phase 3
1,300
Nottingham, Exeter, Liverpool, London, Newcastle, Swansea
2022-05-03
Active, closed
A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer
NCT05091567Small-Cell Lung Cancer
Hoffmann-La Roche
Phase 3
660
Blackpool, GB Manchester, Hull, Leeds, Leicester, London
2021-11-18
Active, closed
A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma
NCT04712097Relapsed or Refractory Follicular Lymphoma
Hoffmann-La Roche
Phase 3
478
Cornwall, Gloucester, London, Nottingham, Torquay
2021-10-27
Active, closed
A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus
NCT04963296Systemic Lupus Erythematosus
Hoffmann-La Roche
Phase 3
303
Cambridge, Leeds, London, Manchester
2021-10-26
Recruiting
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
NCT04929223Metastatic Colorectal Cancer
Hoffmann-La Roche
Phase 1
542
Cambridge, Cardiff, London, Manchester, Sutton
2021-10-22
Active, closed
A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors
NCT04931342Ovarian Cancer
Hoffmann-La Roche
Phase 2
176
Edinburgh, London
2021-10-07
Active, closed
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors
NCT04774718ALK Fusion-positive Solid or CNS Tumors
Hoffmann-La Roche
Phase 1/2
42
London, Manchester, Newcastle upon Tyne
2021-09-14
Active, closed
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
NCT04961996Early Breast Cancer
Hoffmann-La Roche
Phase 3
4,170
Leicester, London, Nottingham, Preston
2021-08-27
Active, closed
A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)
NCT04657289Neovascular Age-related Macular Degeneration (nAMD)
Hoffmann-La Roche
Phase 3
451
Bristol, Liverpool, London, Newcastle upon Tyne, Sunderland, Wolverhampton
2021-07-14
Active, closed
A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease
NCT04777331Parkinsons Disease
Hoffmann-La Roche
Phase 2
586
Dundee, London, Newcastle, Oxford, Peterborough, Plymouth
2021-05-05
Active, closed
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
NCT04873362Breast Cancer
Hoffmann-La Roche
Phase 3
1,188
Blackpool, Brighton, Cambridge, Cheltenham, London, Manchester, Northwood, Preston
2021-05-04
Active, closed
A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy
NCT04660344Muscle-invasive Bladder Cancer
Hoffmann-La Roche
Phase 3
761
Cambridge, Edinburgh, London, Plymouth, Preston, Sheffield, Southampton, Sutton
2021-05-03
Active, closed
A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab
NCT04770896Unresectable Hepatocellular Carcinoma
Hoffmann-La Roche
Phase 3
557
Birmingham, Liverpool, London, Manchester, Newcastle upon Tyne, Oxford
2021-04-26
Active, closed
Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease
NCT04639050Alzheimers Disease
Hoffmann-La Roche
Phase 1/2
241
London
2021-03-15
Active, closed
A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT04408638Diffuse Large B-cell Lymphoma
Hoffmann-La Roche
Phase 3
270
Glasgow, Leeds, London, Manchester, Nottingham
2021-02-23
Active, closed
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
NCT04589845Solid Tumors
Hoffmann-La Roche
Phase 2
920
Glasgow, London, Manchester
2021-01-18
Active, closed
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)
NCT04548999Multiple Sclerosis
Hoffmann-La Roche
Phase 3
769
London, Newcastle upon Tyne, Plymouth
2020-12-03
Active, closed
A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)
NCT04576455Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
Hoffmann-La Roche
Phase 2
303
Harlow, London, Nottingham, Peterborough
2020-11-27
Active, closed
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis
NCT04544449Multiple Sclerosis, Primary Progressive
Hoffmann-La Roche
Phase 3
985
Glasgow, London, Nottingham, Swansea
2020-10-26
Active, closed
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
NCT04546009Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
Hoffmann-La Roche
Phase 3
992
Brighton, Leicester, London, Maidstone, Peterborough, Plymouth, Sutton, Truro
2020-10-09
Active, closed
A Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors
NCT04434092Paroxysmal Nocturnal Hemoglobinuria
Hoffmann-La Roche
Phase 3
210
Leeds, London
2020-10-08
Active, closed
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors
NCT04432584Paroxysmal Nocturnal Hemoglobinuria
Hoffmann-La Roche
Phase 3
190
London
2020-09-30
Active, closed
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma
NCT04246086Follicular Lymphoma
Hoffmann-La Roche
Phase 1/2
237
London, Manchester, Newcastle upon Tyne, Nottingham
2020-08-12
Active, closed
A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
NCT04191499Breast Cancer
Hoffmann-La Roche
Phase 2/3
325
London, Northwood, Oxford, Plymouth
2020-01-29
Active, closed
A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
NCT04077723Lymphoma, Non-Hodgkin
Hoffmann-La Roche
Phase 1/2
498
Leicester, London
2019-08-13
Active, closed
A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis
NCT04035005Multiple Sclerosis, Primary Progressive
Hoffmann-La Roche
Phase 3
1,013
Cardiff, Glasgow, Inverness, London, London, GT LON, Nottingham, Plymouth, Salford
2019-08-12
Recruiting
Extension Study for the Port Delivery System With Ranibizumab (Portal)
NCT03683251Neovascular Age-Related Macular Degeneration
Hoffmann-La Roche
Phase 3
1,000
Bristol, Liverpool, London, Newcastle upon Tyne, Sunderland, Wolverhampton
2018-09-20
Active, closed
A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer
NCT03456076Carcinoma, Non-Small-Cell Lung
Hoffmann-La Roche
Phase 3
257
London, Manchester
2018-08-16
Active, closed
An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
NCT03533283Non-Hodgkins Lymphoma
Hoffmann-La Roche
Phase 1/2
211
Leicester, London, Newcastle upon Tyne
2018-05-08
Recruiting
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
NCT03424005Metastatic Breast Cancer
Hoffmann-La Roche
Phase 1/2
1,132
Glasgow, London
2018-03-30
Active, closed
A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)
NCT03148418Cancer
Hoffmann-La Roche
Phase 3
382
London, Manchester, Metropolitan Borough of Wirral, Nottingham, Surrey
2017-09-20
Active, closed
Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options
NCT02650401Solid Tumors, CNS Tumors
Hoffmann-La Roche
Phase 1/2
69
London, Newcastle upon Tyne
2016-05-03
Active, closed
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
NCT02568267Breast Cancer, Cholangiocarcinoma, Colorectal Cancer, Head and Neck Neoplasms
Hoffmann-La Roche
Phase 2
534
Cambridge, London, Manchester
2015-11-19
Active, closed
Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]
NCT02486718Non-Small Cell Lung Cancer
Hoffmann-La Roche
Phase 3
1,280
Birmingham, Colchester, Essex, London
2015-10-31
Rows per page Showing 1–80 of 80
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 23 September 2026. https://priyalifescience.com/clinical-trials-uk/city/london

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.